CAR T-Cell Therapy Market by End-user, Type and Geography-Forecast and Analysis 2023-2027

CAR T-Cell Therapy Market Forecast 2023-2027:

The Chimeric Antigen Receptor (CAR) T-Cell Therapy Market size is forecast to increase by USD 1.9 billion, at a CAGR of 13.44% between 2022 and 2027. The market's expansion hinges on various factors, notably the rising awareness surrounding CAR T-cell therapy's potential, the escalating rates of blood cancer prevalence, and the surging instances of hematological malignancies. Increased public knowledge about therapy's benefits and its targeted approach to treating cancers is driving demand. The growing incidence of blood cancer, including relapsed or refractory extensive B-cell lymphoma, underscores the urgent need for advanced therapies like treatments. Similarly, the rising cases of hematological malignancies, such as leukemia, are contributing significantly to market growth. These factors collectively highlight the pivotal role of therapy in addressing critical medical needs and driving advancements in cancer treatment.

What will be the Size of the Market During the Forecast Period?

To learn more about this report, View Report Sample

Market Segmentation

This market report extensively covers market segmentation by end-user (hospitals and cancer treatment centers), type (CD19, CD22, BCMA, and others), and geography (North America, Europe, Asia, and Rest of World (ROW)). It also includes an in-depth analysis of drivers, trends, and challenges. Furthermore, the report includes historic market data from 2017 to 2021.

Market Dynamics and Customer Landscape

The market is driven by increasing public awareness and the rising prevalence of cancer, prompting a surge in cancer treatments like CAR T-cell therapy. Advancements in personalized and targeted therapies are shaping trends, offering more effective treatment options. However, challenges such as navigating complex reimbursement policies, ensuring regulatory approvals, and addressing the high cost of CAR T-cell therapies remain. Overcoming these challenges while enhancing the efficacy of CAR T-cell therapy, particularly in cases like relapsed or refractory extensive B-cell lymphoma, is crucial for market growth. Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.

Key Market Driver

Growing awareness regarding CAR T-cell therapy is the key factor driving the growth of the market.  As technology develops and CAR-T cells become more widely known, "armored CARs" are created that interact with cytokines like Interleukin 15 (IL-15) and Interleukin 12 (IL-12) that cause inflammation. It leads to the growth and persistence of CAR T cells at the beginning of immune suppression caused by cancer. Several governments have launched a number of initiatives to increase public awareness of these treatments to fund research into CAR T-cell therapies.

For instance, therapy research and development, as well as numerous research facilities, were funded by the National Cancer Institute (NCI). Additionally, some governments have strengthened their backing for CAR T-cell treatments by introducing numerous initiatives such as new legislation, establishing benevolent reimbursement policies, working with private businesses, and conducting clinical research studies to raise public awareness of CAR T-cell treatments. These initiatives helped more people to become aware of therapy which will increase the market growth during the forecast period.

Significant Market Trends  

One of the growing trends in the market is the rising number of product approvals and clinical trials related to CAR T- cell therapy. In recent years there has been a visible growth in product approval related to CAR T- cell therapy. For Instance, Yescarta was granted FDA approval in February 2022 as the first chimeric antigen receptor (CAR) T-cell therapy for the initial treatment of relapsed or refractory large B-cell lymphoma (LBCL). The first therapy to receive a Category 1 recommendation in the NCCN Treatment Guideline is Yescarta. Similarly, in February 2022, the FDA approved ciltacabtagene autoleucel (Carvykti) for patients with multiple refractory myeloma-that is, multiple myeloma that has failed to respond to treatment. 

According to the clinicaltrials.gov reports of November 23, 2022, there were about 415 clinical trials for CAR-T cell therapies registered, all of which were in various stages of development and covered both ongoing and completed studies, as well as those that are actively recruiting study participants. These factors are considered the driving force of the global CAR T- cell therapy market during the forecast period.

Major Market Challenge

The high cost associated with CAR T-cell therapy is considered to be one of the significant challenges faced by the market. The cost of CAR T-cell therapies is influenced by numerous factors, such as the personalized nature of the therapy, the complex manufacturing process, and the specialized requirements of healthcare infrastructure. For instance, CAR T-cell therapies involve a multi-step process that starts with collecting a patient's own T-cells through leukapheresis. The T-cells are then modified in the laboratory to express a chimeric antigen receptor (CAR) specific to the target antigen, expanded in quantity, and reinfused back into the patient.

However, this manufacturing process requires specialized facilities, equipment, and expertise, which contribute to the overall cost of the therapy. Moreover, CAR T-cell therapies are personalized treatments tailored to each patient. The manufacturing process for each patient is individualized, adding to the complexity and cost. Furthermore, the extensive clinical trials and research involved in developing CAR T-cell therapies also contribute to the overall cost burden. CAR T-cell therapies are not widely available even though there are numerous outstanding results in clinical trials. Such factors will hinder the market growth during the forecast period.

Key Market Customer Landscape

The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.

Global  Market Customer Landscape

Who are the Major Market Players?

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.

ACROBIOSYSTEMS INC: The company offers CAR T-cell therapy called CD37 plus CD22 CAR T, which is in the research phase PCC. 

The research report also includes detailed analyses of the competitive landscape of the market and information about 20 market companies, including:

• Allogene Therapeutics Inc.
• Autolus Therapeutics plc
• Bristol Myers Squibb Co.
• Celyad Oncology SA
• Eli Lilly and Co.
• Fate Therapeutics Inc.
• Gilead Sciences Inc.
• GlaxoSmithKline Plc
• Johnson and Johnson Services Inc.
• Les Laboratoires Servier SAS
• Merck KGaA
• Miltenyi Biotec B.V. and Co. KG
• Noile Immune Biotech Inc.
• Novartis AG
• Pfizer Inc.
• Sangamo Therapeutics Inc.
• Sorrento Therapeutics Inc.
• TCR2 Therapeutics Inc.
• Fortress Biotech Inc.

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

What is the Fastest-Growing Segment in the Market?

The market is a dynamic landscape driven by various critical factors. Cancer treatments and the incidence of cancer play a central role in shaping the demand for CAR T-cell therapy, especially with rising cases globally. Reimbursement policies are also vital, ensuring that patients can access these advanced therapies without financial barriers. Public awareness about CAR T-cell therapy and its effectiveness in treating various cancers is steadily increasing, leading to a growing patient population seeking these innovative treatments. The availability of diverse CAR-T cell therapy products reflects the market's response to the prevalence of different cancer types, including leukemia and lymphoma. The healthcare infrastructure is adapting to accommodate CAR T-cell therapy, emphasizing the need for scaling up manufacturing processes and adopting automated and closed-system technologies to meet the rising demand efficiently. Regulatory approvals and guidelines are crucial in ensuring the efficacy and safety of CAR T-cell therapy across different indications, including relapsed or refractory extensive B-cell lymphoma.

The market share growth by the hospitals segment will be significant during the forecast period. Hospitals provide post-treatment follow-up care to monitor the patient's long-term outcomes, manage any lingering side effects, and detect any signs of disease recurrence or relapse. Hence the growing treatments related to cancer in hospitals are expected to drive the growth of the hospital segment in the global market during the forecast period.

Get a glance at the market contribution of various segments View the PDF Sample

The hospitals segment was valued at USD 752.77 million in 2017 and continued to grow until 2021. Hospitals provide the necessary infrastructure, medical staff, and resources for the administration of CAR T-cell therapies. They have specialized oncology departments or treatment centers equipped to deliver these therapies to eligible patients. Healthcare professionals, including oncologists, hematologists, and nurses, are responsible for managing the treatment process related to therapy, ensuring patient safety, and monitoring the response to therapy.

Moreover, hospitals play a vital role in identifying eligible patients for therapy. They assess patient's medical history, perform diagnostic tests, and evaluate their suitability for treatment. This involves considering factors such as the type and stage of cancer, previous treatment history, and overall health condition. Additionally, they may conduct pre-treatment evaluations, including imaging studies and laboratory tests, to establish a baseline and monitor the patient's progress during and after therapy. Such factors will increase segment growth during the forecast period.

Which are the Key Regions for the Market?

For more insights on the market share of various regions Download PDF Sample now!

North America is estimated to contribute 41% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period. The major reason behind the rising prevalence of chronic illnesses like cancer and autoimmune diseases such as myasthenia gravis (MG), the expansion of research and development activities, and the presence of well-established and powerful market players such as Gilead Sciences, Inc. in the region. Moreover, the rise in investments helps in the expansion of the market.

For instance, in June 2021, Blackstone reported that Cellex Cell Professionals GmbH, the parent company of GEMoaB GmbH, a clinical-stage cell therapy company, and Intellia Therapeutics, Inc. had committed USD 250 million to the launch of a new autologous and allogeneic universal chimeric antigen receptor (CAR) T-cell therapy company. As a result of an increase in cancer cases and the rise in clinical studies in CAR T-Cell therapies, the country is anticipated to experience growth over the forecast period.

Segment Overview

The market report forecasts market growth by revenue at global, regional & country levels and provides a market growth analysis of the latest trends and growth opportunities from 2017 to 2027. 

• End-User Outlook
  • Hospitals
  • Cancer treatment centers

• Type Outlook 
  • CD19
  • CD22
  • BCMA
  • Others

• Region Outlook 
  • North America
    • The U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
    • Rest of Europe
  • Asia
    • China
    • India
  • ROW
    • Austalia
    • Argentina
    • Rest of the World

Market Analyst Overview

The market is witnessing substantial growth driven by advancements in cancer treatments and increasing incidence of cancer worldwide. Innovative CAR T-cell therapy drugs like those offered by companies such as Juno Therapeutics and Tessa Therapeutics are transforming blood cancer treatment, especially for relapsed or refractory extensive B-cell lymphoma and Hematologic malignancies. The rising demand for personalized and targeted therapies, along with developments in precision medicine and genetic modification technologies like CRISPR/Cas9, is enhancing the efficacy and effectiveness of CAR T-cell therapies.

However, challenges persist, including systemic toxicity, high cost, and ensuring product consistency and quality control measures. Overcoming regulatory hurdles and obtaining regulatory approvals and guidelines remain crucial for market players like Adaptimmune and Celgene Corporation. The market's future hinges on scalability, cost-effectiveness, and the ability to tailor treatments for indications like lymphoma, ovarian cancer, and solid tumors. Embracing innovation and patient-centric approaches while addressing financial constraints and government spending on healthcare are key focus areas for sustained growth in the market.

Moreover, the market is witnessing significant growth driven by various key factors. Factors such as patient population demographics, prevalence of cancer, and rates of relapse and remission are crucial determinants. Additionally, the efficacy and safety of T-cell modifications are pivotal in shaping market trends. Moreover, advancements in automated and closed-system technologies are facilitating the scaling up of manufacturing processes, enhancing product consistency and quality control. The development of CAR-T cell therapy products like TT-02 and ADP-A2M4CD8 candidate underscores the industry's focus on tailoring treatments for leukemia and other hematological malignancies.

Furthermore, despite challenges such as the high cost of CAR T-cell therapy, its potential to provide precision in cell-based therapies is driving innovation in immunotherapy. The market's evolution towards more patient-centric and personalized approaches is evident in its response to CD19+ B-cell hematological malignancies and Non-Hodgkin lymphoma. As research continues to explore chimeric antigen receptors (CARs), there's growing optimism for achieving a cure for these challenging diseases through CAR T-cell therapy.

Market Scope
Report Coverage	Details
Page number	153
Base year	2022
Historic period	2017-2021
Forecast period	2023-2027
Growth momentum & CAGR	Accelerate at a CAGR of 13.44%
Market growth 2023-2027	USD 1.9 billion
Market structure	Fragmented
YoY growth 2022-2023(%)	13.12
Regional analysis	North America, Europe, Asia, and the Rest of the World (ROW)
Performing market contribution	North America at 41%
Key countries	US, Germany, UK, China, and Japan
Competitive landscape	Leading companies, Market Positioning of companies, Competitive Strategies, and Industry Risks
Key companies profiled	ACROBIOSYSTEMS INC., Allogene Therapeutics Inc., Autolus Therapeutics plc, Bristol Myers Squibb Co., Celyad Oncology SA, Eli Lilly and Co., Fate Therapeutics Inc., Gilead Sciences Inc., GlaxoSmithKline Plc, Johnson and Johnson Services Inc., Les Laboratoires Servier SAS, Merck KGaA, Miltenyi Biotec B.V. and Co. KG, Noile Immune Biotech Inc., Novartis AG, Pfizer Inc., Sangamo Therapeutics Inc., Sorrento Therapeutics Inc., TCR2 Therapeutics Inc., and Fortress Biotech Inc.
Market dynamics	Parent market analysis, Market forecasting, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period.
Customization purview	If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

View PDF Sample

What are the Key Data Covered in this Market Research Report?

• CAGR of the market during the forecast period
• Detailed information on factors that will drive the growth of the market between 2023 and 2027
• Precise estimation of the market  size and its contribution to the market in focus on the parent market
• Accurate predictions about upcoming trends and changes in consumer behavior
• Growth of the market across North America, Europe, Asia, and the Rest of the World (ROW)
• Thorough market research and growth analysis of the market’s competitive landscape and detailed information about companies
• Comprehensive market growth and forecasting analysis of factors that will challenge the growth of market companies

We can help! Our analysts can customize this market research report to meet your requirements. 

Get in touch